The following list represents Studies for which calls for participation are currently open. Learn about the individual studies below, and click the link to find out more about the Working Party responsible for the study.
Dear Colleague,
Prophylaxis with LMV in adult CMV-seropositive patients became a breakthrough strategy in allo-HCT setting. Study of Russo et al. (Lancet Haematology 2024) showed that LMV prophylaxis for 200 days after HCT is efficacious and safe.
The Infectious Diseases Working Party of EBMT wants to estimate if LMV prophylaxis for more than 270 days after HCT is justified in selected patients.
We ask you to participate in a short survey on extended use of LMV. It will take you no more than 3 minutes to answer all questions.
If you're not working at a centre performing allo HCT, please let us know so we can remove you from the mailing list. Please know, this invite is sent to the PI and IDWP members of your centre.
We'de appreciate your answer by July 25.
Kind regards,
Jan Styczynski (Study PI)
Dina Averbuch (Chair of IDWP)
Nina Knelange (Study coordinator lead)
Gloria Tridello (Statistician)